FierceBiotech Special Report: Armed Antibodies Readied for War on Cancer
In the endless match between oncologists and cancer, the scoreboard has long read “Advantage: Cancer.” That's not to say oncology hasn’t won a set or two. But in far too many cases the end is inevitable: Cancer rallies with a vengeance.
Today, there are some 25 Antibody-drug conjugates (ADC) in clinical trials in the U.S., and dozens more in early preclinical development. In August 2011, the FDA approved the first new ADC since Mylotarg, Seattle Genetics' Adcetris, for treatment of systemic anaplastic large cell lymphoma and Hodgkin lymphoma.
For the drug developers looking to bring these products to market, ADCs represent the inevitable marriage of two sometimes hit-or-miss technologies, chemotherapy and antibodies, the next generation of anti-cancer compounds. They clearly anticipate the marriage to be fruitful. The excitement over ADCs stems from their apparent ability to extract the best from both antibodies and toxins, with apparently few of the downsides of either.
To read more about the potential and the challenges of the burgeoning field of ADCs, download the complete report today.
| Wednesday, November 4th | 11:00AM ET / 8:00AM PT | Presented By: Oracle
Attend this webcast for an interactive panel discussion around the findings of a blinded industry survey on eSource in clinical trials – including current and anticipated growth, capabilities critical to eSource, and expected vs. actual benefits. Reserve Your Spot Today!
FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 150,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today!